Haemonetics (HAE) AI Stock Analysis

• Market Cap: $3.45B
• Dividend Yield: N/A
• Average Volume (3M): 706.93K
• Price to Earnings (P/E): 20.9
• Beta (1Y): 0.82
• Revenue Growth: 8.14%
• EPS Growth: 2.55%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.24
• Shares Outstanding: 50,237,465
• 10 Day Avg. Volume: 694,114
• 30 Day Avg. Volume: 706,926
• PEG Ratio: 4.93
• Price to Book (P/B): 3.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 35.71
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 0.81
• Enterprise Value/Gross Profit: 6.02
• Enterprise Value/Ebitda: 3.99
• 1Y Price Target: $92.25
• Price Target Upside: 32.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

Haemonetics' overall stock score reflects a balanced view of its strengths and challenges. Strong financial performance, particularly in revenue growth and profitability, is a key strength, while technical analysis indicates current bearish trends. Valuation is moderate, and recent earnings call details highlight both growth opportunities and areas needing attention. Positive corporate events offer potential for reinforcing leadership and strategy.

Positive Factors

Financial Performance

Haemonetics generated $330.6 million in revenue, exceeding the consensus estimate of $329.4 million.

Margin Expansion

HAE's gross margin was up 620 bps Y/Y and its operating margin was up 610 bps Y/Y.

Market Position

The outlook looks bright as the company captures material share, benefits from continued pricing gains, and collections improve.

Negative Factors

Plasma Segment Challenges

The plasma business declined 9.1% on a reported basis and was down 8.9% organically.

Revenue Guidance

Management provided FY26 revenue and EPS guidance that was below consensus at the midpoints.

Stock Performance

The stock has seen a steady decline due to concerns like slowing base plasma collections and the rate of VASCADE XL uptake.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation is a global healthcare company that specializes in providing blood and plasma supplies and services. The company operates in the healthcare sector, focusing on blood management solutions that enhance patient care and improve operational efficiency in hospitals and blood centers. Haemonetics offers a range of products, including plasma collection systems, blood cell separators, and surgical blood salvage systems, catering to hospitals, blood banks, and plasma collection centers worldwide.

How the Company Makes Money

Haemonetics makes money primarily through the sale of its blood management devices and related services. Its revenue streams are driven by the sale of plasma collection systems, which are used by plasma collection centers to efficiently and safely collect plasma from donors. Additionally, the company generates income from its hospital products division, which provides surgical blood salvage systems and blood cell separators used in various medical procedures. Haemonetics also engages in long-term supply agreements and partnerships with healthcare institutions and blood centers, ensuring a steady demand for its products and services. These partnerships and the recurring nature of its business model, through the continuous need for consumables and maintenance of its equipment, contribute significantly to its earnings.

Haemonetics Financial Statement Overview

Summary

Haemonetics shows strong revenue growth and improving profitability with a solid Income Statement score of 85, indicating operational efficiency. However, the Balance Sheet score of 75 reflects moderate leverage, and the Cash Flow score of 70 highlights declining free cash flow, indicating a need for improved cash flow management.

Income Statement

Haemonetics has demonstrated strong revenue growth, with a notable Revenue Growth Rate of 17.49% from 2022 to 2023 and 12% from 2023 to TTM. The Gross Profit Margin for TTM is robust at 52.38%, and the Net Profit Margin has improved to 9.47% in TTM, indicating efficient cost management. EBIT and EBITDA margins are healthy at 15.02% and 19.15% respectively, showcasing operational efficiency.

Balance Sheet

The balance sheet shows a moderate Debt-to-Equity Ratio of 1.35 in TTM, indicating a balanced leverage position. The Return on Equity has improved to 14.34% in TTM, reflecting effective utilization of shareholder funds. However, the Equity Ratio at 35.82% suggests a moderate reliance on debt financing, which could pose risks if not managed carefully.

Cash Flow

Haemonetics has shown a decrease in Free Cash Flow, with a decline of 17.06% in TTM compared to the previous year. The Operating Cash Flow to Net Income Ratio is 0.99, indicating close alignment between cash generation and profitability. The Free Cash Flow to Net Income Ratio stands at 0.74, suggesting adequate but slightly declining cash flow conversion from profits.

Breakdown
TTM	Mar 2024	Jun 2023	Jun 2022	Jun 2021	Mar 2020
Income Statement		Total Revenue
1.37B	1.31B	1.17B	993.20M	870.46M	988.48M
	Gross Profit
719.40M	691.55M	615.10M	505.50M	397.84M	484.51M
	EBIT
206.27M	164.88M	156.03M	80.75M	57.96M	153.95M
	EBITDA
294.04M	265.58M	249.34M	178.50M	142.25M	264.24M
	Net Income Common Stockholders
130.06M	117.56M	115.40M	43.38M	79.47M	76.53M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
178.80M	178.80M	284.47M	259.50M	192.31M	137.31M
	Total Assets
2.20B	2.20B	1.93B	1.86B	1.82B	1.27B
	Total Debt
873.88M	807.79M	765.89M	773.59M	707.61M	382.49M
	Net Debt
695.08M	628.99M	481.42M	514.09M	515.30M	245.18M
	Total Liabilities
1.24B	1.24B	1.12B	1.11B	1.09B	680.00M
	Stockholders Equity
959.96M	959.96M	818.00M	749.42M	731.67M	587.11M
Cash Flow		Free Cash Flow
95.93M	115.45M	162.87M	75.75M	71.77M	109.46M
	Operating Cash Flow
129.25M	181.75M	273.06M	172.26M	108.81M	158.22M
	Investing Cash Flow
-192.99M	-322.39M	-143.79M	-86.34M	-425.44M	-57.18M
	Financing Cash Flow
196.77M	38.16M	-100.36M	-15.75M	367.45M	-131.21M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 69.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Positive. The current price of 69.38 is above the 20-day moving average (MA) of 63.30, above the 50-day MA of 63.42, and below the 200-day MA of 73.23, indicating a neutral trend. The MACD of 1.85 indicates Negative momentum. The RSI at 64.57 is Neutral, neither overbought nor oversold. The STOCH value of 81.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATR	78 Outperform	$10.15B	28.09	15.15%	1.15%	0.34%	17.27%
HAE	69 Neutral	$3.45B	20.92	18.83%	―	8.14%	2.55%
ICUI	69 Neutral	$3.53B	―	-4.62%	―	7.19%	-56.19%
BDX	68 Neutral	$49.02B	32.63	5.97%	2.33%	5.84%	15.12%
HOLX	66 Neutral	$12.34B	23.54	11.77%	―	1.66%	21.95%
TFX	58 Neutral	$5.60B	39.96	3.48%	1.07%	0.29%	-48.98%
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%

Haemonetics Corporate Events

Haemonetics Announces Key Executive Leadership Changes

Haemonetics Corporation announced executive leadership updates on March 3, 2025, appointing Frank W. Chan, Ph.D. as Executive Vice President, Chief Operating Officer, effective April 7, 2025, and promoting Roy Galvin to Executive Vice President, Chief Commercial Officer. Chan, with over 25 years of experience in medical device and healthcare technology, will oversee research, development, and global manufacturing, while Galvin will expand his role to include the Global Hospital business. These appointments aim to strengthen Haemonetics’ leadership and support its long-term growth strategy.